Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis.
Fiche publication
Date publication
février 2020
Journal
Breast cancer research and treatment
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier
Tous les auteurs :
Paracha N, Reyes A, Diéras V, Krop I, Pivot X, Urruticoechea A
Lien Pubmed
Résumé
In the absence of head-to-head trial data, network meta-analysis (NMA) was used to compare trastuzumab emtansine (T-DM1) with other approved treatments for previously treated patients with unresectable or metastatic HER2-positive breast cancer (BC).
Mots clés
Capecitabine, Lapatinib, Locally advanced, Neratinib, Pertuzumab, Trastuzumab emtansine
Référence
Breast Cancer Res. Treat.. 2020 Feb 25;: